Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 35

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q9P2H5

UPID:
UBP35_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 35; Ubiquitin thioesterase 35; Ubiquitin-specific-processing protease 35

ALTERNATIVE UPACC:
Q9P2H5

BACKGROUND:
The enzyme Ubiquitin carboxyl-terminal hydrolase 35, with its aliases Deubiquitinating enzyme 35, Ubiquitin thioesterase 35, and Ubiquitin-specific-processing protease 35, is pivotal in the ubiquitin-proteasome pathway. This pathway is critical for the regulated degradation of proteins, influencing cell cycle progression, DNA repair, and signal transduction. The enzyme's deubiquitinating activity is essential for maintaining cellular protein balance and ensuring proper cellular function.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Ubiquitin carboxyl-terminal hydrolase 35 holds promise for uncovering new therapeutic avenues. Given its central role in the ubiquitin-proteasome system, manipulating its activity could offer a strategy for treating conditions linked to dysfunctional protein degradation, such as cancer and neurodegeneration. Developing inhibitors or activators of this enzyme could provide a means to correct protein homeostasis imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.